UPMC Hillman Cancer Center | Strategic Alliance Partners

Adam M. Brufsky, MD, PhD, discusses the impact of the COVID-19 pandemic on patients with cancer, as well as the science behind the proposed explanation of the immunopathology of COVID-19.

Robert L. Ferris, MD, PhD, discusses ongoing research with STING agonists and checkpoint inhibitors in head and neck cancer.

Robert L. Ferris, MD, PhD, director of University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Hillman Professor of Oncology, associate vice chancellor for cancer research, professor of otolaryngology, immunology, and radiation oncology, co-director, Tumor Microenvironment Center, UPMC Hillman Cancer Center, discusses a clinical trial testing ADU-S100/MIW815 plus pembrolizumab (Keytruda) in patients with head and neck cancer.

Adam M. Brufsky, MD, PhD, highlightes the treatment landscape in HER2-positive breast cancer, remaining sequencing questions, and the growing utility of neratinib in the paradigm.

James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.

Investigators are testing the hypothesis that administering cetuximab with an anti–PD-L1 agent will induce immunostimulatory synergy and prolong survival in patients with cutaneous squamous cell carcinoma.

James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.

Adam M. Brufsky, MD, PhD, FACP, discusses the use of neratinib and the importance of expanding the treatment portfolio in HER2-positive metastatic breast cancer.

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

Adam M. Brufsky, MD, PhD, discusses case ascertainment bias regarding the coronavirus 2019.

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

John T. Comerci, MD, discusses the utility of primary debulking surgery in ovarian cancer.

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.

Jason J. Luke, MD, FACP, discusses predictive biomarkers in metastatic melanoma.

Jessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.

Adam M. Brufsky, MD, PhD, FACP, discusses the emergence of biosimilars in oncology and how he anticipates they will change the paradigm.

Sarah E. Taylor, MD, discusses molecular testing recommendations in ovarian cancer.

Michelle M. Boisen, MD, discusses the selection of neoadjuvant chemotherapy versus upfront surgery for women with newly diagnosed ovarian cancer.

Brian Orr, MD, an assistant professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at University of Pittsburgh Medical Center, discusses ongoing biomarker research for immunotherapy in ovarian cancer.

Jessica Layne Berger, MD, discusses the frontline treatment options in newly diagnosed ovarian cancer.

Jason J. Luke, MD, FACP, discusses current and emerging treatment paradigms in metastatic melanoma.

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Adam M. Brufsky, MD, PhD, discusses the utility of trastuzumab biosimilars in breast cancer.

Robert L. Ferris, MD, PhD, discusses combining STING agonists with checkpoint inhibitors in head and neck cancer.

Antoinette Wozniak, MD, FACP, FASCO, discusses sequencing with immunotherapy and chemoradiation in select patients with stage III lung cancer.